We attended the ASCO 2022 annual meeting in Chicago. We came away encouraged from the meeting. The unmet medical need in oncology remains high and new technologies and diagnostic approaches have started to make in-roads into the market. While opportunities will become smaller due to better patient stratification, and competition and complexity is significantly increasing, we believe that all the same strong new winners will evolve (bispecifics, ADC’s, cell therapies, ctDNA testing).